NEWS & EVENTS

Takeda and Shattuck Labs Announce Collaboration to Explore ARC Fusion Proteins in Immuno-Oncology
Read morePress Release 2017

Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Read moreFromm et.al Journal for ImmunoTherapy of Cancer, 18 December 2018

Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (PD1-Fc-OX40L), for Cancer Immunotherapy
Read moreSITC 2018

Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (SIRPα-Fc-CD40L), for Cancer Immunotherapy
Read moreSITC 2018

Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (TIM3-Fc-OX40L and TIM3-Fc-CD40L), for Cancer Immunotherapy
Read moreSITC 2018